Overexpression of AHNAK2 and loss of VHL and CDKN2A are correlated with poor prognosis in patients with ccRCC [24, 25], and are generally used as prognostic markers for ccRCC. Here, AHNAK2 is linked to nonpapillary renal cell carcinoma.